Atomoxetine Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:458780865
Width:220
Width2:240
Tradename:Strattera, others
Dailymedid:Atomoxetine
Pregnancy Au:B3
Pregnancy Au Comment:[1]
Routes Of Administration:Oral (Swallowed by mouth)
Class:Selective norepinephrine reuptake inhibitor
Atc Prefix:N06
Atc Suffix:BA09
Legal Au:S4
Legal Br:C1
Legal Br Comment:[2]
Legal Ca:Rx-only
Legal Uk:POM
Legal Uk Comment:[3]
Legal Us:Rx-only
Legal Eu:Rx-only
Legal Eu Comment:[4]
Bioavailability:63 to 94%[5] [6]
Protein Bound:98%
Metabolism:Liver, via CYP2D6
Elimination Half-Life:4.5–25 hours
Excretion:Kidney (80%) and faecal (17%)
Index2 Label:as HCl
Cas Number:83015-26-3
Cas Number2:82248-59-7
Pubchem:54841
Pubchem2:54840
Iuphar Ligand:7118
Drugbank:DB00289
Drugbank2:DBSALT001207
Chemspiderid:49516
Chemspiderid2:ID49515
Unii:ASW034S0B8
Unii2:57WVB6I2W0
Kegg:D07473
Kegg2:D02574
Chebi:127342
Chebi2:331697
Chembl:641
Chembl2:1702
Synonyms:(R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine
Iupac Name:(3R)-N-Methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
C:17
H:21
N:1
O:1
Smiles:CC1=C(C=CC=C1)O[C@H](CCNC)C2=CC=CC=C2
Stdinchi:1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
Stdinchikey:VHGCDTVCOLNTBX-QGZVFWFLSA-N

Atomoxetine, sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD)[7] and, to a lesser extent, cognitive disengagement syndrome.[8] [9] [10] It may be used alone or along with psychostimulants.[11] [12] It enhances the executive functions of self-motivation, sustained attention, inhibition, working memory, reaction time[13] and emotional self-regulation.[14] [15] Use of atomoxetine is only recommended for those who are at least six years old. It is taken orally. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate.

Common side effects of atomoxetine include abdominal pain, loss of appetite, nausea, feeling tired, and dizziness.[7] Serious side effects may include angioedema, liver problems, stroke, psychosis, heart problems, suicide, and aggression.[7] [16] There is a lack of data regarding its safety during pregnancy; as of 2019, its safety during pregnancy and for use during breastfeeding is not certain.[17]

It was approved for medical use in the United States in 2002.[7] In 2021, it was the 219th most commonly prescribed medication in the United States, with more than 1.9million prescriptions.[18] [19]

Medical uses

Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

Attention deficit hyperactivity disorder

Atomoxetine is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under six years old.[20] One of the primary differences with the standard stimulant treatments for ADHD is that it has little known abuse potential. Meta-analyses and systematic reviews have found that atomoxetine has comparable efficacy and equal tolerability to methylphenidate in children and adolescents. In adults, efficacy and tolerability are equivalent.[21] [22] [23] [24]

While its efficacy may be less than that of amphetamine,[25] there is some evidence that it may be used in combination with stimulants.[11] Doctors may prescribe non-stimulants including atomoxetine when a person has bothersome side effects from stimulants; when a stimulant was not effective; in combination with a stimulant to increase effectiveness;[26] [27] when the cost of stimulants is prohibitive; or when there is concern about the abuse potential of psychostimulants in a patient with a history of drug use disorder.

Atomoxetine alleviates ADHD symptoms through norepinephrine reuptake and by indirectly increasing dopamine in the pre-frontal cortex,[28] sharing 70-80% of the brain regions with stimulants in their produced effects.[29]

Unlike α2 adrenoceptor agonists such as guanfacine and clonidine, atomoxetine's use can be abruptly stopped without significant discontinuation effects being seen.

The initial therapeutic effects of atomoxetine usually take 1 to 4 weeks to become apparent.[30] [31] A further 2 to 4 weeks may be required for the full therapeutic effects to be seen.[32] Incrementally increasing response may occur up to 1 year or longer.[33] The maximum recommended total daily dose in children and adolescents over 70 kg and adults is 100 mg.[34]

Other uses

Cognitive disengagement syndrome

Atomoxetine may be used to treat cognitive disengagement syndrome (CDS),[35] as multiple randomised controlled clinical trials (RCTs) have found that it is an effective treatment.[36] [37] [38] In contrast, multiple RCTs have shown that it responds poorly to the stimulant medication methylphenidate.[39] [40] [41] [42]

Traumatic brain injury

Atomoxetine is sometimes used in the treatment of cognitive impairment and frontal lobe symptoms due to conditions like traumatic brain injury (TBI).[43] [44] It is used with the goal of treating ADHD-like symptoms such as sustained attentional problems, disinhibition,[45] lack of arousal, fatigue, and depression, including symptoms from cognitive disengagement syndrome. A 2015 Cochrane review identified only one study of atomoxetine for TBI and found no positive effects.[46] Aside from TBI, atomoxetine was found to be effective in the treatment of akinetic mutism following subarachnoid hemorrhage in a case report.[47]

Contraindications

Contraindications include:

Adverse effects

Common side effects include abdominal pain, loss of appetite, nausea, feeling tired, and dizziness. Serious side effects may include angioedema, liver problems, stroke, psychosis, heart problems, suicide, and aggression. A 2020 meta-analysis found that atomoxetine was associated with anorexia, weight loss, and hypertension, rating it as a "potentially least preferred agent based on safety" for treating ADHD.[48] [49] As of 2019, safety in pregnancy and breastfeeding is not clear; a 2018 review stated that, "[b]ecause of lack of data, the treatingphysician should consider stopping atomoxetine treatment in women with ADHD during pregnancy."[50]

The U.S. Food and Drug Administration (FDA) has issued a black box warning for suicidal behavior/ideation. Similar warnings have been issued in Australia.[51] Unlike stimulant medications, atomoxetine does not have abuse liability or the potential to cause withdrawal effects on abrupt discontinuation.[52]

Overdose

Atomoxetine is relatively non-toxic in overdose. Single-drug overdoses involving over 1500 mg of atomoxetine have not resulted in death.

Interactions

Atomoxetine is a substrate for CYP2D6. Concurrent treatment with a CYP2D6 inhibitor such as bupropion, fluoxetine, or paroxetine has been shown to increase plasma atomoxetine by 100% or more, as well as increase N-desmethylatomoxetine levels and decrease plasma 4-hydroxyatomoxetine levels by a similar degree.[53] [54] [55]

Atomoxetine has been found to directly inhibit hERG potassium currents with an IC50 of 6.3 μM, which has the potential to cause arrhythmia.[54] [56] QT prolongation has been reported with atomoxetine at therapeutic doses and in overdose; it is suggested that atomoxetine not be used with other medications that may prolong the QT interval, concomitantly with CYP2D6 inhibitors, and caution to be used in poor metabolizers.[54]

Other notable drug interactions include:

Pharmacology

Pharmacodynamics

Atomoxetine (and metabolites)[59] [60]
Site
77 43
5 3 92
1,451
>1,000
>1,000
>1,000
2,000 1,000 1,700
>1,000
>1,000
11,400 20,000 19,600
29,800 >30,000 >10,000
18,000 56,100 32,100
>100,000 >100,000 >100,000
>100,000 >100,000 >100,000
>10,000 >10,000 >10,000
>10,000 >10,000 >10,000
12,100 >100,000 >100,000
Antagonist 422
300
Partial Agonist 95
>1,000
200 >30,000 >10,000
0.66 - 3,470a
10,900b
12,400b
6,500b
6,300 20,000 5,710
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. All values are for human receptors unless otherwise specified. arat cortex. bXenopus oocytes. Additional sources:

Atomoxetine inhibits the presynaptic norepinephrine transporter (NET), preventing the reuptake of norepinephrine throughout the brain along with inhibiting the reuptake of dopamine in specific brain regions such as the prefrontal cortex, where dopamine transporter (DAT) expression is minimal.[57] In rats, atomoxetine increased prefrontal cortex catecholamine concentrations without altering dopamine levels in the striatum or nucleus accumbens; in contrast, methylphenidate, a dopamine reuptake inhibitor, was found to increase prefrontal, striatal, and accumbal dopamine levels to the same degree.[61] [62] In addition to rats, atomoxetine has also been found to induce similar region-specific catecholamine level alteration in mice.[63]

Atomoxetine's status as a serotonin transporter (SERT) inhibitor at clinical doses in humans is uncertain. A PET imaging study on rhesus monkeys found that atomoxetine occupied >90% and >85% of neural NET and SERT, respectively.[64] However, both mouse and rat microdialysis studies have failed to find an increase in extracellular serotonin in the prefrontal cortex following acute or chronic atomoxetine treatment.[62] [63] Supporting atomoxetine's selectivity, a human study found no effects on platelet serotonin uptake (a marker of SERT inhibition) and inhibition of the pressor effects of tyramine (a marker of NET inhibition).[65]

Atomoxetine has been found to act as an NMDA receptor antagonist in rat cortical neurons at therapeutic concentrations.[66] [67] It causes a use-dependent open-channel block and its binding site overlaps with the Mg2+ binding site.[66] [67] Atomoxetine's ability to increase prefrontal cortex firing rate in anesthetized rats could not be blocked by D1 or α1-adrenergic receptor antagonists, but could be potentiated by NMDA or an α2-adrenergic receptor antagonist, suggesting a glutaminergic mechanism.[68] In Sprague Dawley rats, atomoxetine reduces NR2B protein content without altering transcript levels.[69] Aberrant glutamate and NMDA receptor function have been implicated in the etiology of ADHD.[70] [71]

Atomoxetine also reversibly inhibits GIRK currents in Xenopus oocytes in a concentration-dependent, voltage-independent, and time-independent manner.[72] Kir3.1/3.2 ion channels are opened downstream of M2, α2, D2, and A1 stimulation, as well as other Gi-coupled receptors.[72] Therapeutic concentrations of atomoxetine are within range of interacting with GIRKs, especially in CYP2D6 poor metabolizers.[72] It is not known whether this contributes to the therapeutic effects of atomoxetine in ADHD.

4-Hydroxyatomoxetine, the major active metabolite of atomoxetine in CYP2D6 extensive metabolizers, has been found to have sub-micromolar affinity for opioid receptors, acting as an antagonist at μ-opioid receptors and a partial agonist at κ-opioid receptors.[73] It is not known whether this action at the kappa-opioid receptor leads to CNS-related adverse effects.

Pharmacokinetics

Orally administered atomoxetine is rapidly and completely absorbed.[57] First-pass metabolism by the liver is dependent on CYP2D6 activity, resulting in an absolute bioavailability of 63% for extensive metabolizers and 94% for poor metabolizers.[57] Maximum plasma concentration is reached in 1–2 hours.[57] If taken with food, the maximum plasma concentration decreases by 10-40% and delays the tmax by 3 hours.[57] Drugs affecting gastric pH have no effect on oral bioavailability.

Following intravenous delivery, atomoxetine has a volume of distribution of 0.85 L/kg (indicating distribution primarily in total body water), with limited partitioning into red blood cells.[57] [74] It is highly bound to plasma proteins (98.7%), mainly albumin, along with α1-acid glycoprotein (77%) and IgG (15%).[57] [58] Its metabolite N-desmethylatomoxetine is 99.1% bound to plasma proteins, while 4-hydroxyatomoxetine is only 66.6% bound.[57]

The half-life of atomoxetine varies widely between individuals, with an average range of 4.5 to 19 hours.[57] [75] As atomoxetine is metabolized by CYP2D6, exposure may be increased 10-fold in CYP2D6 poor metabolizers.[75] Among CYP2D6 extensive metabolizers, the half-life of atomoxetine averaged 5.34 hours and the half-life of the active metabolite N-desmethylatomoxetine was 8.9 hours.[57] [76] By contrast, among CYP2D6 poor metabolizers the half-life of atomoxetine averaged 20.0 hours and the half-life of N-desmethylatomoxetine averaged 33.3 hours.[57] [76] Steady-state levels of atomoxetine are typically achieved at or around day 10 of regular dosing, with trough plasma concentrations (Ctrough) residing around 30–40°ng/mL; however, both the time to steady-state levels and Ctrough are expected to vary based on a patient's CYP2D6 profile.[77] [78]

Atomoxetine, N-desmethylatomoxetine, and 4-hydroxyatomoxetine produce minimal to no inhibition of CYP1A2 and CYP2C9, but inhibit CYP2D6 in human liver microsomes at concentrations between 3.6 and 17 μmol/L. Plasma concentrations of 4-hydroxyatomoxetine and N-desmethylatomoxetine at steady state are 1.0% and 5% that of atomoxetine in CYP2D6 extensive metabolizers, and are 5% and 45% that of atomoxetine in CYP2D6 poor metabolizers.

Atomoxetine is excreted unchanged in urine at <3% in both extensive and poor CYP2D6 metabolizers, with >96% and 80% of a total dose being excreted in urine, respectively.[57] The fractions excreted in urine as 4-hydroxyatomoxetine and its glucuronide account for 86% of a given dose in extensive metabolizers, but only 40% in poor metabolizers.[57] CYP2D6 poor metabolizers excrete greater amounts of minor metabolites, namely N-desmethylatomoxetine and 2-hydroxymethylatomoxetine and their conjugates.[57]

Pharmacogenomics

Chinese adults homozygous for the hypoactive CYP2D6*10 allele have been found to exhibit two-fold higher area-under-the-curve (AUCs) and 1.5-fold higher maximum plasma concentrations compared to extensive metabolizers.[57]

Japanese men homozygous for CYP2D6*10 have similarly been found to experience two-fold higher AUCs compared to extensive metabolizers.[57]

Chemistry

Atomoxetine, or (−)-methyl[(3''R'')-3-(2-methylphenoxy)-3-phenylpropylamine, is a white, granular powder that is highly soluble in water. <gallery> File:Strattera 60mg capsule back.jpg|Strattera 60-mg capsule back File:Lilly Strattera 60mg Capsule.jpg|Strattera 60-mg capsule front with Lilly logo </gallery> ===Synthesis=== [[File:Atomoxetine-synthesis.png|thumb|none|1000px|Original synthesis of atomoxetine, as patented by [[Eli Lilly and Company]][79] [80] ]]

Detection in biological fluids

Atomoxetine may be quantitated in plasma, serum or whole blood in order to distinguish extensive versus poor metabolizers in those receiving the drug therapeutically, to confirm the diagnosis in potential poisoning victims or to assist in the forensic investigation in a case of fatal overdosage.[81]

History

Atomoxetine is manufactured, marketed, and sold in the United States as the hydrochloride salt (atomoxetine HCl) under the brand name Strattera by Eli Lilly and Company, the original patent-filing company and current U.S. patent owner. Atomoxetine was initially intended to be developed as an antidepressant, but it was found to be insufficiently efficacious for treating depression. It was, however, found to be effective for ADHD and was approved by the FDA in 2002, for the treatment of ADHD. Its patent expired in May 2017.[82] On 12 August 2010, Lilly lost a lawsuit that challenged its patent on Strattera, increasing the likelihood of an earlier entry of a generic into the US market.[83] On 1 September 2010, Sun Pharmaceuticals announced it would begin manufacturing a generic in the United States.[84] In a 29 July 2011 conference call, however, Sun Pharmaceutical's Chairman stated "Lilly won that litigation on appeal so I think [generic Strattera]'s deferred."[85]

In 2017 the FDA approved the generic production of atomoxetine by four pharmaceutical companies.[86]

Society and culture

The drug was originally known as tomoxetine. It was renamed to avoid medication errors, as the name may be confused with tamoxifen.[87]

Brand names

In India, atomoxetine is sold under brand names including Axetra, Axepta, Attera, Tomoxetin, and Attentin. In Australia, Canada, Italy, Portugal, Romania, Spain, Switzerland and the US, atomoxetine is sold under the brand name Strattera. In the Czech Republic it is sold under brand names including Mylan. In Poland, it is sold under the brand name Auroxetyn. In Iran, atomoxetine is sold under brand names including Stramox. In Brazil, it is sold under the brand name Atentah. In 2017, a generic version was approved in the United States.

Research

There has been some suggestion that atomoxetine might be a helpful adjunct in people with major depression, particularly in cases with concomitant ADHD.[88]

Atomoxetine may be used in those with ADHD and bipolar disorder although such use has not been well studied.[89] Some benefit has also been seen in people with ADHD and autism.[90] As with other norepinephrine reuptake inhibitors it appears to reduce anxiety and depression symptoms, although attention has focused mainly on specific patient groups such as those with concurrent ADHD[91] or methamphetamine dependence.[92]

Further reading

Notes and References

  1. Web site: Atomoxetine (Strattera) Use During Pregnancy . Drugs.com . 22 August 2019 . 7 February 2020 . 22 March 2019 . https://web.archive.org/web/20190322181637/https://www.drugs.com/pregnancy/atomoxetine.html . live .
  2. Web site: Anvisa . Brazilian Health Regulatory Agency . 15 September 2023 . RDC Nº 816 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 816 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20231019120956/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-816-de-15-de-setembro-de-2023-510390164 . 19 October 2023 . 19 October 2023 . . pt-BR . 18 September 2023.
  3. Web site: Strattera 10mg hard capsules - Summary of Product Characteristics (SmPC) . (emc) . 8 February 2021 . 11 June 2022 . 8 October 2021 . https://web.archive.org/web/20211008174322/https://www.medicines.org.uk/emc/product/5531/smpc . live .
  4. Web site: Active substance(s): atomoxetine . List of nationally authorised medicinal products. European Medicines Agency . 2016 . 12 June 2022 . 12 June 2022 . https://web.archive.org/web/20220612030231/https://www.ema.europa.eu/en/documents/psusa/atomoxetine-list-nationally-authorised-medicinal-products-psusa/00000262/201511_en.pdf . live .
  5. Web site: Atomoxetine (Rx) – Strattera. Medscape Reference. WebMD. 10 November 2013. https://web.archive.org/web/20131110153513/http://reference.medscape.com/drug/strattera-atomoxetine-342994. 10 November 2013. live.
  6. Web site: Atomoxetine Hydrochloride capsule [Mylan Pharmaceuticals Inc.]]. DailyMed. Mylan Pharmaceuticals Inc.. October 2011. 10 November 2013. https://web.archive.org/web/20131110152856/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdab7205-d0ff-41c3-8430-2d399dfaa759. 10 November 2013. live.
  7. Web site: Atomoxetine Hydrochloride Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 22 March 2019 . https://web.archive.org/web/20190404041202/https://www.drugs.com/monograph/atomoxetine-hydrochloride.html . 4 April 2019 . live .
  8. McBurnett K, Clemow D, Williams D, Villodas M, Wietecha L, Barkley R . Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms . Journal of Child and Adolescent Psychopharmacology . 27 . 1 . 38–42 . February 2017 . 27845858 . 10.1089/cap.2016.0115 .
  9. Becker SP, Willcutt EG, Leopold DR, Fredrick JW, Smith ZR, Jacobson LA, Burns GL, Mayes SD, Waschbusch DA, Froehlich TE, McBurnett K, Servera M, Barkley RA . Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome . Journal of the American Academy of Child and Adolescent Psychiatry . 62 . 6 . 629–645 . June 2023 . 36007816 . 9943858 . 10.1016/j.jaac.2022.07.821 .
  10. Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K . Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial . Journal of Child and Adolescent Psychopharmacology . 23 . 9 . 605–613 . November 2013 . 24206099 . 3842866 . 10.1089/cap.2013.0054 .
  11. Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ . A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability . Journal of Child and Adolescent Psychopharmacology . 23 . 3 . 179–193 . April 2013 . 23560600 . 3696926 . 10.1089/cap.2012.0093 .
  12. Web site: https://web.archive.org/web/20170202064443/https://www.psychiatry.org/patients-families/adhd/what-is-adhd . Guidelines (Tertiary source) . 2 February 2017 . Parent's Medication Guide: ADHD . June 2013 . American Psychiatric Association . American Psychiatric Association & American Academy of Child and Adolescent Psychiatry (AACAP). Though not FDA-approved for combined treatment, atomoxetine (Strattera) is sometimes used in conjunction with stimulants as an off-label combination therapy.. live . 1 January 2017.
  13. Isfandnia F, El Masri S, Radua J, Rubia K . The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis . Neuroscience and Biobehavioral Reviews . 162 . 105703 . July 2024 . 38718988 . 10.1016/j.neubiorev.2024.105703 .
  14. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, Albatti TH, Aljoudi HF, Alqahtani MM, Asherson P, Atwoli L, Bölte S, Buitelaar JK, Crunelle CL, Daley D, Dalsgaard S, Döpfner M, Espinet S, Fitzgerald M, Franke B, Gerlach M, Haavik J, Hartman CA, Hartung CM, Hinshaw SP, Hoekstra PJ, Hollis C, Kollins SH, Sandra Kooij JJ, Kuntsi J, Larsson H, Li T, Liu J, Merzon E, Mattingly G, Mattos P, McCarthy S, Mikami AY, Molina BS, Nigg JT, Purper-Ouakil D, Omigbodun OO, Polanczyk GV, Pollak Y, Poulton AS, Rajkumar RP, Reding A, Reif A, Rubia K, Rucklidge J, Romanos M, Ramos-Quiroga JA, Schellekens A, Scheres A, Schoeman R, Schweitzer JB, Shah H, Solanto MV, Sonuga-Barke E, Soutullo C, Steinhausen HC, Swanson JM, Thapar A, Tripp G, van de Glind G, van den Brink W, Van der Oord S, Venter A, Vitiello B, Walitza S, Wang Y . The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder . Neuroscience and Biobehavioral Reviews . 128 . 789–818 . September 2021 . 33549739 . 8328933 . 10.1016/j.neubiorev.2021.01.022 .
  15. Kamradt JM, Ullsperger JM, Nikolas MA . Executive function assessment and adult attention-deficit/hyperactivity disorder: tasks versus ratings on the Barkley deficits in executive functioning scale . Psychological Assessment . 26 . 4 . 1095–1105 . December 2014 . 24885846 . 10.1037/pas0000006 .
  16. Book: British national formulary : BNF 76. 2018. Pharmaceutical Press. 9780857113382. 344–345. 76.
  17. Web site: Atomoxetine Pregnancy and Breastfeeding Warnings . Drugs.com . 3 March 2019 . https://web.archive.org/web/20190322181637/https://www.drugs.com/pregnancy/atomoxetine.html . 22 March 2019 . live .
  18. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  19. Web site: Atomoxetine - Drug Usage Statistics . ClinCalc . 14 January 2024 . 7 October 2021 . https://web.archive.org/web/20211007114138/https://clincalc.com/DrugStats/Drugs/Atomoxetine . live .
  20. Web site: Strattera (atomoxetine hydrochloride). TGA eBusiness Services. Eli Lilly Australia Pty. Limited. 21 August 2013. 10 November 2013. https://web.archive.org/web/20170406152455/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04269-3. 6 April 2017. live.
  21. Hanwella R, Senanayake M, de Silva V . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis . BMC Psychiatry . 11 . 176 . November 2011 . 22074258 . 3229459 . 10.1186/1471-244X-11-176 . free .
  22. Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B . Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis . Medical Journal of the Islamic Republic of Iran . 30 . 325 . 10 February 2016 . 27390695 . 4898838 .
  23. Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW . Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis . Journal of Attention Disorders . 15 . 8 . 674–683 . November 2011 . 20837981 . 10.1177/1087054710379737 . 7 December 2023 . live . 43503227 . https://web.archive.org/web/20231115073753/http://journals.sagepub.com/doi/10.1177/1087054710379737 . 15 November 2023 .
  24. Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V . A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients . Journal of Psychopharmacology . 30 . 5 . 444–458 . May 2016 . 27005307 . 10.1177/0269881116636105 . 7 December 2023 . live . 104938 . https://web.archive.org/web/20230523141246/https://journals.sagepub.com/doi/10.1177/0269881116636105 . 23 May 2023 .
  25. Stuhec M, Munda B, Svab V, Locatelli I . Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion . Journal of Affective Disorders . 178 . 149–159 . June 2015 . 25813457 . 10.1016/j.jad.2015.03.006 .
  26. Web site: Attention Deficit Hyperactivity Disorder . National Institute of Mental Health (NIMH) . 21 July 2018 . https://web.archive.org/web/20161225231931/https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml . 25 December 2016 . live .
  27. Web site: Mental Health Medications . NIMH. 17 May 2019 . https://web.archive.org/web/20190406082433/https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml#part_149861 . 6 April 2019 . live .
  28. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T . July 2010 . Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice . Journal of Neurochemistry . 114 . 1 . 259–270 . 10.1111/j.1471-4159.2010.06750.x . 20403082.
  29. Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH . September 2012 . Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder . Archives of General Psychiatry . 69 . 9 . 952–961 . 10.1001/archgenpsychiatry.2011.2053 . 22945622.
  30. Bushe CJ, Savill NC . Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety . Journal of Psychopharmacology . 28 . 3 . 204–211 . March 2014 . 23438503 . 10.1177/0269881113478475 . 793033 . free .
  31. Childress AC . A critical appraisal of atomoxetine in the management of ADHD . Therapeutics and Clinical Risk Management . 12 . 27–39 . 2016 . 26730199 . 4694693 . 10.2147/TCRM.S59270 . free .
  32. Book: 978-0-470-97948-8 . The Maudsley prescribing guidelines in psychiatry . Taylor D, Paton C, Shitij K . 2012 . Wiley-Blackwell . West Sussex .
  33. Clemow DB, Bushe CJ . Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients . Journal of Psychopharmacology . 29 . 12 . 1221–1230 . December 2015 . 26349559 . 10.1177/0269881115602489 . 22649093 .
  34. Web site: Strattera- atomoxetine hydrochloride capsule . 29 January 2020 . DailyMed.gov . Eli Lilly and Company . 26 February 2020 . https://web.archive.org/web/20180607120316/https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb&type=pdf&name=309de576-c318-404a-bc15-660c2b1876fb . 7 June 2018 . live . dmy-all .
  35. Becker SP, Willcutt EG, Leopold DR, Fredrick JW, Smith ZR, Jacobson LA, Burns GL, Mayes SD, Waschbusch DA, Froehlich TE, McBurnett K, Servera M, Barkley RA . Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome . Journal of the American Academy of Child and Adolescent Psychiatry . 62 . 6 . 629–645 . June 2023 . 36007816 . 9943858 . 10.1016/j.jaac.2022.07.821 .
  36. Becker SP, Willcutt EG, Leopold DR, Fredrick JW, Smith ZR, Jacobson LA, Burns GL, Mayes SD, Waschbusch DA, Froehlich TE, McBurnett K, Servera M, Barkley RA . Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome . Journal of the American Academy of Child and Adolescent Psychiatry . 62 . 6 . 629–645 . June 2023 . 36007816 . 9943858 . 10.1016/j.jaac.2022.07.821 .
  37. McBurnett K, Clemow D, Williams D, Villodas M, Wietecha L, Barkley R . Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms . Journal of Child and Adolescent Psychopharmacology . 27 . 1 . 38–42 . February 2017 . 27845858 . 10.1089/cap.2016.0115 .
  38. Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K . Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial . Journal of Child and Adolescent Psychopharmacology . 23 . 9 . 605–613 . November 2013 . 24206099 . 3842866 . 10.1089/cap.2013.0054 .
  39. Fırat S, Gul H, Aysev A . An Open-Label Trial of Methylphenidate Treating Sluggish Cognitive Tempo, Inattention, and Hyperactivity/Impulsivity Symptoms Among 6- to 12-Year-Old ADHD Children: What Are the Predictors of Treatment Response at Home and School? . Journal of Attention Disorders . 25 . 9 . 1321–1330 . July 2021 . 32064995 . 10.1177/1087054720902846 . 211134241 .
  40. Froehlich TE, Becker SP, Nick TG, Brinkman WB, Stein MA, Peugh J, Epstein JN . Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial . The Journal of Clinical Psychiatry . 79 . 2 . 17m11553 . 2018 . 29489078 . 6558969 . 10.4088/JCP.17m11553 .
  41. Barkley RA, DuPaul GJ, McMurray MB . Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate . Pediatrics . 87 . 4 . 519–531 . April 1991 . 10.1542/peds.87.4.519 . 2011430 . 23501657 . 28 February 2024 . 28 February 2024 . https://web.archive.org/web/20240228221621/https://pubmed.ncbi.nlm.nih.gov/2011430/ . live .
  42. Book: Barkley RA . Concentration deficit disorder (sluggish cognitive tempo). . Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment. . The Guilford Press . 2015 . 81–115 . https://www.peterraabe.ca/docs/SCT_Barkley.pdf . 28 February 2024 . 16 January 2024 . https://web.archive.org/web/20240116211606/https://peterraabe.ca/docs/SCT_Barkley.pdf . live .
  43. Ripley DL . Atomoxetine for individuals with traumatic brain injury . The Journal of Head Trauma Rehabilitation . 21 . 1 . 85–88 . 2006 . 16456396 . 10.1097/00001199-200601000-00010 .
  44. Arnts H, van Erp WS, Lavrijsen JC, van Gaal S, Groenewegen HJ, van den Munckhof P . On the pathophysiology and treatment of akinetic mutism . Neuroscience and Biobehavioral Reviews . 112 . 270–278 . May 2020 . 32044373 . 10.1016/j.neubiorev.2020.02.006 . free . 211053123 . free . 2066/225901 .
  45. Termine C, Selvini C, Rossi G, Balottin U . Emerging treatment strategies in Tourette syndrome: what's in the pipeline? . International Review of Neurobiology . 112 . 445–80 . 2013 . 24295630 . 10.1016/B978-0-12-411546-0.00015-9 . Atomoxetine is a nonstimulant drug used to treat ADHD (Perwien et al., 2006) that acts as a presynaptic blocker of noradrenalin reuptake (Swanson et al., 2006). .
  46. Dougall D, Poole N, Agrawal N . Pharmacotherapy for chronic cognitive impairment in traumatic brain injury . The Cochrane Database of Systematic Reviews . 12 . CD009221 . December 2015 . 26624881 . 10.1002/14651858.CD009221.pub2 . 11092927 .
  47. Kim YW, Shin JC, An YS . Treatment of chronic akinetic mutism with atomoxetine: subtraction analysis of brain f-18 fluorodeoxyglucose positron emission tomographic images before and after medication: a case report . Clinical Neuropharmacology . 33 . 4 . 209–211 . July 2010 . 20661027 . 10.1097/WNF.0b013e3181dca948 .
  48. Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU . Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects . World Psychiatry . 19 . 2 . 214–232 . June 2020 . 32394557 . 7215080 . 10.1002/wps.20765 . Meta-analysis .
  49. 1 September 2020 . Psychiatric drugs given to children and adolescents have been ranked in order of safety . NIHR Evidence . Plain English summary . 10.3310/alert_40795 . 241309451 . 12 March 2022 . 21 January 2022 . https://web.archive.org/web/20220121102841/https://evidence.nihr.ac.uk/alert/psychiatric-drugs-given-to-children-and-adolescents-have-been-ranked-in-order-of-safety/ . live .
  50. Ornoy A . Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation . Pharmaceutical Research . 35 . 3 . 46 . February 2018 . 29411149 . 10.1007/s11095-017-2323-z . Review . 3663423 .
  51. Atomoxetine and suicidality in children and adolescents. October 2013. Australian Prescriber . 4 . 5 . 166 . 10 November 2013. https://web.archive.org/web/20150330113305/http://www.australianprescriber.com/magazine/36/5/166/9 . 30 March 2015 . dead . dmy .
  52. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D . Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment . Journal of Clinical Psychopharmacology . 24 . 1 . 30–35 . February 2004 . 14709944 . 10.1097/01.jcp.0000104907.75206.c2 . 37636280 .
  53. Todor I, Popa A, Neag M, Muntean D, Bocsan C, Buzoianu A, Vlase L, Gheldiu AM, Briciu C . Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers . Journal of Pharmacy & Pharmaceutical Sciences . 19 . 2 . 198–207 . April–June 2016 . 27518170 . 10.18433/j3h03r . free .
  54. Kasi PM, Mounzer R, Gleeson GH . Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system . Case Reports in Medicine . 2011 . 952584 . 2011 . 21765848 . 3135225 . 10.1155/2011/952584 . free .
  55. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW . Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics . Journal of Clinical Pharmacology . 42 . 11 . 1219–1227 . November 2002 . 12412820 . 10.1177/009127002762491307 . 40283275 . free .
  56. Scherer D, Hassel D, Bloehs R, Zitron E, von Löwenstern K, Seyler C, Thomas D, Konrad F, Bürgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP . Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents . British Journal of Pharmacology . 156 . 2 . 226–236 . January 2009 . 19154426 . 2697834 . 10.1111/j.1476-5381.2008.00018.x .
  57. Sauer JM, Ring BJ, Witcher JW . 2005 . Clinical pharmacokinetics of atomoxetine . Clinical Pharmacokinetics . 44 . 6 . 571–590 . 10.2165/00003088-200544060-00002 . 15910008 . 25708096.
  58. Web site: 21-411 Strattera Clinical Pharmacology Biopharmaceutics Review Part 2. U.S. Food and Drug Administration (FDA). 6 August 2017. https://web.archive.org/web/20170301134914/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P2.pdf. 1 March 2017. live.
  59. Web site: PDSP Ki Database . Psychoactive Drug Screening Program (PDSP) . Roth BL, Driscol J . Bryan Roth . University of North Carolina at Chapel Hill and the United States National Institute of Mental Health . 14 August 2017 . 27 August 2021 . https://web.archive.org/web/20210827232047/https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=atomoxetine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query . live .
  60. Upadhyaya HP, Desaiah D, Schuh KJ, Bymaster FP, Kallman MJ, Clarke DO, Durell TM, Trzepacz PT, Calligaro DO, Nisenbaum ES, Emmerson PJ, Schuh LM, Bickel WK, Allen AJ . A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder . Psychopharmacology . 226 . 2 . 189–200 . March 2013 . 23397050 . 3579642 . 10.1007/s00213-013-2986-z . Springer Nature .
  61. Hodgkins P, Shaw M, McCarthy S, Sallee FR . The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter? . CNS Drugs . 26 . 3 . 245–268 . March 2012 . 22329564 . 10.2165/11599630-000000000-00000 .
  62. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW . Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder . Neuropsychopharmacology . 27 . 5 . 699–711 . November 2002 . 12431845 . 10.1016/S0893-133X(02)00346-9 . free .
  63. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T . Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice . Journal of Neurochemistry . 114 . 1 . 259–270 . July 2010 . 20403082 . 10.1111/j.1471-4159.2010.06750.x . free .
  64. Ding YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J, Weinzimmer D, McCarthy TJ, Carson RE, Huang Y, Laruelle M . Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD . NeuroImage . 86 . 164–171 . February 2014 . 23933039 . 10.1016/j.neuroimage.2013.08.001 . The noradrenergic action also exerts an important clinical effect in different antidepressant classes such as desipramine and nortriptyline (tricyclics, prevalent noradrenergic effect), reboxetine and atomoxetine (relatively pure noradrenergic reuptake inhibitor (NRIs)), and dual action antidepressants such as the serotonin noradrenaline reuptake inhibitors (SNRIs), the noradrenergic and dopaminergic reuptake inhibitor (NDRI) bupropion, and other compounds (e.g., mianserin, mirtazapine), which enhance the noradrenergic transmission . 16958660 .
  65. Zerbe RL, Rowe H, Enas GG, Wong D, Farid N, Lemberger L . Clinical pharmacology of tomoxetine, a potential antidepressant . The Journal of Pharmacology and Experimental Therapeutics . 232 . 1 . 139–143 . January 1985 . 3965689 .
  66. Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weigt HU, Fegert JM, Boeckers TM, Föhr KJ . Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations . British Journal of Pharmacology . 160 . 2 . 283–291 . May 2010 . 20423340 . 2874851 . 10.1111/j.1476-5381.2010.00707.x .
  67. Barygin OI, Nagaeva EI, Tikhonov DB, Belinskaya DA, Vanchakova NP, Shestakova NN . Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics . Brain Research . 1660 . 58–66 . April 2017 . 28167075 . 10.1016/j.brainres.2017.01.028 . 27647092 .
  68. Di Miceli M, Gronier B . Psychostimulants and atomoxetine alter the electrophysiological activity of prefrontal cortex neurons, interaction with catecholamine and glutamate NMDA receptors . Psychopharmacology . 232 . 12 . 2191–2205 . June 2015 . 25572531 . 10.1007/s00213-014-3849-y . 18339166 .
  69. Udvardi PT, Föhr KJ, Henes C, Liebau S, Dreyhaupt J, Boeckers TM, Ludolph AG . Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study . Drug Design, Development and Therapy . 7 . 1433–1446 . 2013 . 24348020 . 3857115 . 10.2147/DDDT.S50448 . free .
  70. Maltezos S, Horder J, Coghlan S, Skirrow C, O'Gorman R, Lavender TJ, Mendez MA, Mehta M, Daly E, Xenitidis K, Paliokosta E, Spain D, Pitts M, Asherson P, Lythgoe DJ, Barker GJ, Murphy DG . Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS study . Translational Psychiatry . 4 . 3 . e373 . March 2014 . 24643164 . 3966039 . 10.1038/tp.2014.11 .
  71. Chang JP, Lane HY, Tsai GE . Attention deficit hyperactivity disorder and N-methyl-D-aspartate (NMDA) dysregulation . Current Pharmaceutical Design . 20 . 32 . 5180–5185 . 2014 . 24410567 . 10.2174/1381612819666140110115227 .
  72. Kobayashi T, Washiyama K, Ikeda K . Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine . Neuropsychopharmacology . 35 . 7 . 1560–1569 . June 2010 . 20393461 . 3055469 . 10.1038/npp.2010.27 .
  73. Creighton CJ, Ramabadran K, Ciccone PE, Liu J, Orsini MJ, Reitz AB . Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect . Bioorganic & Medicinal Chemistry Letters . 14 . 15 . 4083–4085 . August 2004 . 15225731 . 10.1016/j.bmcl.2004.05.018 .
  74. Web site: atomoxetine HC. FDA. 30 November 2023. 18 October 2023. https://web.archive.org/web/20231018171341/https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021411s004s012s013s015s021lbl.pdf. live.
  75. Brown JT, Bishop JR . Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability . Pharmacogenomics . 16 . 13 . 1513–1520 . 2015 . 26314574 . 10.2217/PGS.15.93 .
  76. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA . Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism . Drug Metabolism and Disposition . 31 . 1 . 98–107 . January 2003 . 12485958 . 10.1124/dmd.31.1.98 . 13032441 .
  77. Sauer JM, Ring BJ, Witcher JW . Clinical pharmacokinetics of atomoxetine . Clinical Pharmacokinetics . 44 . 6 . 571–590 . 2005 . 15910008 . 10.2165/00003088-200544060-00002 . 25708096 .
  78. Encyclopedia: Chamberlain SR, Sahakian BJ . Atomoxetine . 2010 . Encyclopedia of Psychopharmacology . 158–160 . Stolerman IP . Berlin, Heidelberg . Springer . en . 10.1007/978-3-540-68706-1_35 . 978-3-540-68706-1 .
  79. US. 4018895 A. patent. Aryloxyphenylpropylamines in treating depression. 19 April 1977. 17 September 1975. 1974-01-10. Bryan B. Molloy. Klaus K. Schmiegel. Eli Lilly And Company.
  80. US. EP0052492 B1. patent. 3-aryloxy-3-phenylpropylamines. 29 February 1984. 13 November 1981. 1980-11-14. Bennie Joe Foster. Edward Ralph Lavagnino. Eli Lilly And Company.
  81. Book: Baselt RC . Disposition of Toxic Drugs and Chemicals in Man . 8th . Biomedical Publications . Foster City, CA . 2008 . 118–20 . 978-0-931890-08-6 . registration .
  82. Web site: Patent and Exclusivity Search Results . 26 April 2009 . Electronic Orange Book . U.S. Food and Drug Administration (FDA) . https://web.archive.org/web/20120322100021/http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021411&Product_No=002&table1=OB_Rx . 22 March 2012 . live .
  83. Web site: Lilly loses ADD patent case, cuts revenue outlook . Reuters . 2010-08-12 . 2024-07-23.
  84. News: Sun Pharma receives USFDA approval for generic Strattera capsules . International Business Times . dead . https://web.archive.org/web/20110407100949/http://www.ibtimes.com/articles/48022/20100901/sun-pharma-usfda-strattera-capsules-eli-lilly-atomoxetine-hydrochloride-attention-deficit-hyperactiv.htm . 7 April 2011 .
  85. News: Sun Pharma Q1 2011-12 Earnings Call Transcript 10.00 am, July 29, 2011 . dead . https://web.archive.org/web/20110929013747/http://www.sunpharma.com/images/finance/FY12%20Q1%20Earnings%20Call%20Transcript.pdf . 29 September 2011 .
  86. FDA approves first generic Strattera for the treatment of ADHD. 30 May 2017. U.S. Food and Drug Administration (FDA) . 1 January 2018. https://web.archive.org/web/20170604122624/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm561096.htm. 4 June 2017. live.
  87. Ledbetter M . Atomoxetine: a novel treatment for child and adult ADHD . Neuropsychiatric Disease and Treatment . 2 . 4 . 455–466 . December 2006 . 19412494 . 2671957 . 10.2147/nedt.2006.2.4.455 . free .
  88. Book: Malenka RC, Nestler EJ, Hyman SE, Holtzman DM . Molecular Neuropharmacology: A Foundation for Clinical Neuroscience . 2015 . McGraw-Hill Medical . New York . 9780071827706 . 3rd.
  89. Perugi G, Vannucchi G . The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder . Expert Opinion on Pharmacotherapy . 16 . 14 . 2193–2204 . 2015 . 26364896 . 10.1517/14656566.2015.1079620 . 28907560 .
  90. Book: Autism Society of America . Siegel M, Erickson C, Frazier JA, Ferguson T, Goepfert E, Joshi G, Humberd QM, King BH, Lutz A, Kraus L, Mao A, Robb A, Veenstra-VanderWeele J, Wang P, Head CJ . Autism Spectrum Disorder Parents Medication Guide . American Academy of Child and Adolescent Psychiatry . 2016 . Washington, DC . 13 . Atomoxetine (Strattera) has also been researched in controlled studies for treatment of ADHD in children with autism, and showed some improvements, particularly for hyperactivity and impulsivity . live . https://web.archive.org/web/20170411220740/https://www.aacap.org/App_Themes/AACAP/Docs/resource_centers/autism/Autism_Spectrum_Disorder_Parents_Medication_Guide.pdf . 11 April 2017.
  91. Snircova E, Marcincakova-Husarova V, Hrtanek I, Kulhan T, Ondrejka I, Nosalova G . Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD . Pediatrics International . 58 . 6 . 476–481 . June 2016 . 26579704 . 10.1111/ped.12847 . 6229741 .
  92. Rabiey A, Hassani-Abharian P, Farhad M, Moravveji AR, Akasheh G, Banafshe HR . Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy . Archives of Iranian Medicine . 22 . 12 . 692–698 . December 2019 . 31823620 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Atomoxetine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.